IQVIA Holdings Inc. (NYSE:IQV) Stock Holdings Lessened by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. lowered its stake in IQVIA Holdings Inc. (NYSE:IQV) by 1.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 49,636 shares of the medical research company’s stock after selling 728 shares during the period. PNC Financial Services Group Inc.’s holdings in IQVIA were worth $9,754,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Capital Performance Advisors LLP bought a new position in shares of IQVIA in the third quarter valued at $27,000. Synergy Asset Management LLC bought a new position in shares of IQVIA in the fourth quarter valued at $33,000. Avior Wealth Management LLC grew its position in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares in the last quarter. Assetmark Inc. grew its position in IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares in the last quarter. Finally, Ashton Thomas Securities LLC purchased a new position in IQVIA during the 3rd quarter worth approximately $57,000. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on IQV shares. Stephens started coverage on shares of IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective on the stock. JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. UBS Group lowered their price objective on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Truist Financial reiterated a “buy” rating and set a $263.00 price objective (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Finally, Robert W. Baird lowered their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st. Five analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Stock Down 2.7 %

IQVIA stock opened at $183.72 on Wednesday. The firm has a market cap of $32.39 billion, a price-to-earnings ratio of 24.50, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $261.72. The firm has a fifty day moving average price of $197.36 and a two-hundred day moving average price of $211.78.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.